News

13 May 2026

PExA partner in Dutch precision medicine project within COPD and interstitial lung diseases

PExA has become an industrial partner in the Dutch research project COPD-PARASOL-ILD, which forms part of the national precision medicine initiative P4O2. The project aims to identify and validate biomarkers for improved diagnosis and treatment monitoring in chronic lung diseases such as COPD and interstitial lung disease (ILD).  Other partners in the project are amongst…

Read more
20 Apr 2026

Additional funding strengthens a growing research environment in Örebro where PExA is used in multiple studies

PExA announces that the Company’s instrument and method are playing an increasingly clear role in the growing research environment at Örebro University and Region Örebro County, focused on occupational particle exposure and early biomarkers of lung effects.  Örebro University and Region Örebro County have been awarded SEK 2.4 million from Nyckelfonden 2026 for the RESPIMARK…

Read more
17 Mar 2026

PExA highlights the potential for early detection of lung diseases at Life Science Day – presentation now available online

At Life Science Day in Gothenburg on March 4, Tomas Gustafsson, CEO of PExA AB, presented the company’s technology for collecting biological material from the small airways through analysis of particles in exhaled air. A recording of the presentation is now available online. PExA’s instrument enables non-invasive sampling from the smallest airways of the lung—an area where…

Read more

Archive

Categories